XCancer

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Description:

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

Phase 1/2

Contacts:

Heiko Schöder, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03631017 - Click here to see study on

ClinicalTrials.gov

PARPi-FL

Isotope(s):
Target(s):
  • PARP
Ligand Class: Small Molecules
Inclusion
  • Part 1:
  • Biopsy (histologically or cytologically) proven Squamos Cell Carcinoma
  • ECOG performance status 0 or 1
  • Age ≥18 years
  • Oral cavity, oropharynx, or nasopharynx primary site
Exclusion
  • * Significantly impaired organ function that may interfere with the excretion and metabolism of the imaging agent. Specifically, patients will be excluded if they meet the following criteria:
  • Hepatic
  • Bilirubin \>2.0 x ULN (institutional upper limits of normal)
  • Hematologic o Platelets \<75K/mcL
  • AST/ALT \>2.5 x ULN